Caris Starts Onyx Pharma (ONXX) at Above Average
More News related to ONXX
- Onyx Pharmaceuticals (ONXX) VP and Chief Medical Officer Resigns
- Onyx Pharmaceuticals Reports Third Quarter and Nine-Month 2008 Financial Results
- Onyx Pharmaceuticals Licenses Rights to Novel Targeted Oncology Agent From BTG International
- Onyx Pharmaceuticals to Present at the 2008 Credit Suisse Health Care Conference
- New Analyses Confirm Nexavar's Efficacy and Safety in Multiple Patient Subsets With Liver Cancer
More News related to New Coverage
- Sources Say 'Highly Unlikely' That Miller Buys Yahoo! (YHOO) -CNBC
- Reports Former AOL CEO Raising Money For Yahoo! (YHOO) Deal
- Former AOL CEO John Miller In Talks With PE Shops To Buy Yahoo (YHOO)
- Reports Total Is Preparing A Bid For NEXEN (NXY)
- NEXEN (NXY) Pops On Buyout Talk
Caris & Co. initiates coverage on Onyx Pharmaceuticals (Nasdaq: ONXX) with an Above Average rating.
Onyx Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes oral anticancer therapies designed to prevent cancer cell proliferation and angiogenesis by inhibiting proteins that signal or support tumor growth in the United States and internationally.
Related Categories
New CoverageStocks Mentioned
+0.93Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
